Newsletter Subject

FDA Gives Nod to Gene Therapy for Hemophilia A

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Thu, Jun 29, 2023 10:52 PM

Email Preheader Text

Daily Headlines Thursday, June 29, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT

[MEDPAGE TODAY]( Daily Headlines Thursday, June 29, 2023 Today's Top Stories for {NAME} [ONCOLOGY/HEMATOLOGY]( [FDA Gives Nod to Gene Therapy for Hemophilia A]( [INFECTIOUS DISEASE]( ['Jarringly' Low Hep C Cure Rates a Decade After New Treatments, CDC Says]( [NEUROLOGY]( [Dementia Risk Tied to Menopausal Hormone Therapy, Even in Women 55 and Younger]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Advancing Shared Decision-Making and Patient-Centered Treatment in the Management of HER2-Negative and Triple Negative Breast Cancer]( [POP MEDICINE]( [Doctor No-No's; Leaving Residency for Reality TV; Debunking COVID Misinfo]( [MEETING COVERAGE]( [Bispecific Antibodies in Relapsed/Refractory DLBCL]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [ONCOLOGY/HEMATOLOGY]( [Young Cancer Survivors at Increased Lifetime Risk of Mental Health Disorders]( CME SPOTLIGHT [Novel Immunotherapeutic Approaches in Relapsed/Refractory Multiple Myeloma]( [PULMONOLOGY]( [Cardiorespiratory Fitness Levels May Influence Cancer Risk in Men]( [PSYCHIATRY]( [Suicide Attempts Nearly 8 Times Higher Among Transgender People, Study Shows]( [PAIN MANAGEMENT]( [Opioids No Better for Acute Neck and Back Pain Than Non-Opioid Treatment]( CME SPOTLIGHT [Novel Mechanisms and Therapeutic Targets in Relapsed/Refractory Multiple Myeloma]( [SPECIAL REPORTS]( [Waste Company's 'Concealed Human Torso' Suit; Impostor Nurse Reportedly Rips Out IVs]( [ENDOCRINOLOGY]( [First Cellular Therapy Approved for Type 1 Diabetes]( [ONCOLOGY/HEMATOLOGY]( [WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer]( CME SPOTLIGHT [Employing Collaborative Care Strategies for the Management of Pediatric Patients With Hodgkin Lymphoma]( [OPINION]( [Threats to Democracy Are Threats to Health]( [ENDOCRINOLOGY]( [FDA Panel Backs Palovarotene for Ultra-Rare Bone Disorder]( [MEETING COVERAGE]( [Adjuvant Immunotherapy in Early-Stage NSCLC]( CME SPOTLIGHT [Transforming Patient-Centered Care for HR+/HER2- Breast Cancer Patients Through Collaborative Learning: A Toolkit for Clinical Teams]( [PRACTICE MANAGEMENT]( [Setting Up Technology in Your Private Practice]( [ONCOLOGY/HEMATOLOGY]( [TXA Holds Its Own for Heavy Menstrual Bleeding in von Willebrand Disease]( [ASCO READING ROOM]( [Abhishek Tripathi, MD, on Eligibility Criteria in Advanced Urothelial Cancer Trials]( CME SPOTLIGHT [Uncovering the Under-Diagnosed in MDS: The MDS Diagnostic Accelerator Hub]( [HOSPITAL-BASED MEDICINE]( [New Guidance to Stem the Tide of MRSA Spread in Hospitals]( [MEETING COVERAGE]( [SecondLine Treatments for Kidney Cancer]( [CARDIOLOGY]( [Vitamin D for Cardiovascular Prevention Runs Into Another Wall]( # Weekly Survey [Lab-Grown Meat: Yea or Nay?]( The Department of Agriculture [approved the sale]( of lab-grown meat, which proponents say will greatly reduce the environmental impacts of meat production[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-06-29&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.